Dark

ENTA
Enanta Pharmaceuticals, Inc
stock NASDAQ

At Close

Jun 4, 2025 3:59:30 PM EDT

7.10USD-1.252%(-0.09)141,124

7.09Bid 7.12Ask 0.03Spread

Pre-market

0.00USD-100.000%(-7.19)0

After-hours

Jun 4, 2025 4:00:30 PM EDT

7.11USD+0.141%(+0.01)653

OverviewOptionsHistoricalExchangesShortsNews

Jan 13, 2022

12:02PM EST What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals Benzinga

11:45AM EST 10 Biggest Price Target Changes For Thursday Benzinga

11:44AM EST SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Lowers Price Target to $80 Benzinga

Jan 6, 2022

07:00AM EST Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 4, 2022

07:00AM EST Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Nov 24, 2021

11:13AM EST Where Enanta Pharmaceuticals Stands With Analysts Benzinga

07:39AM EST Oppenheimer Maintains Perform on Enanta Pharmaceuticals, Raises Price Target to $73 Benzinga

Nov 23, 2021

07:17AM EST JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Raises Price Target to $116 Benzinga

06:29AM EST SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Lowers Price Target to $85 Benzinga

Nov 22, 2021

04:08PM EST Enanta Pharma Q4 Loss/share $1.22 Vs. Loss $1.46 Year Ago RTTNews

04:03PM EST Enanta Pharmaceuticals Q4 EPS $(1.22), Inline, Sales $23.60M Miss $26.34M Estimate Benzinga

04:01PM EST Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire

03:54AM EST Earnings Scheduled For November 22, 2021 Benzinga

Nov 21, 2021

03:05PM EST The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week Benzinga

Nov 19, 2021

11:32AM EST Enanta Pharmaceuticals's Earnings: A Preview Benzinga

08:47AM EST RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $72 Benzinga

08:20AM EST The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial Benzinga

08:06AM EST JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Lowers Price Target to $111 Benzinga

07:15AM EST Safety Signals Force Enanta To Stop EDP-721 HBV Program Benzinga

07:00AM EST Enanta Pharmaceuticals to Participate in December Investor Conferences Business Wire

Nov 18, 2021

04:01PM EST Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program Business Wire

Nov 15, 2021

04:01PM EST Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 Business Wire

Nov 12, 2021

07:17AM EST Enanta Pharma Reports Final Data From Phase 1b Study Of EDP-514: Was Safe, Well Tolerated Up To 800mg Benzinga

07:15AM EST Enanta Pharma Reports Positive Data From Phase 1b Studies RTTNews

07:05AM EST Enanta Reports Positive Data From Phase 1b Studies Of EDP-514, Hepatitis B Virus Core Inhibitor RTTNews

07:00AM EST Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor Business Wire

Nov 8, 2021

11:25AM EST Expert Ratings For Enanta Pharmaceuticals Benzinga

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

07:24AM EST 10 Biggest Price Target Changes For Monday Benzinga

07:14AM EST JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Raises Price Target to $121 Benzinga

06:11AM EST SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Raises Price Target to $92 Benzinga

Oct 20, 2021

09:03AM EDT RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Raises Price Target to $74 Benzinga

07:32AM EDT JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Raises Price Target to $77 Benzinga

Oct 19, 2021

10:42AM EDT Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022 Benzinga

08:14AM EDT Enanta Pharmaceuticals Inc. (ENTA) presented preclinical data of EDP-235, the company's Lead oral protease inhibitor designed for the treatment of COVID-19, at the ISIRV-WHO Virtual Conference 2021, demonstrating potent inhibition of SARS-CoV-2 replication. RTTNews

07:14AM EDT Enanta Pharma Presents New Data For EDP-235, Lead Oral Protease Inhibitor Designed For Treatment Of COVID-19 RTTNews

07:11AM EDT Enanta Pharmaceuticals Highlights Presentation Of EDP-235 Data At World Health Organization (WHO) Virtual Conference 2021 Benzinga

07:02AM EDT Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV-WHO Virtual Conference 2021 Business Wire

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 7, 2021

12:21PM EDT Where Enanta Pharmaceuticals Stands With Analysts Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 Benzinga

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

05:08AM EDT Jefferies Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $95 Benzinga

Oct 6, 2021

08:27AM EDT Enanta Pharmaceuticals To Present EDP-235 Preclinical Data At ISRIV-WHO Virtual 2021 Conference Oct. 19 Benzinga

08:25AM EDT Enanta Pharma To Present New Preclinical Data For EDP-235 For COVID-19 At ISRIV-WHO Virtual 2021 Conference RTTNews

08:16AM EDT New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment Business Wire

Oct 5, 2021

07:00AM EDT Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference Business Wire

Oct 4, 2021

07:05AM EDT Enanta Pharma says its EDP-297 Was Not Substantially Differentiated from EDP-305 Based on Phase 1 Results, Will Discontinue its ARGO-2 Trial Evaluating EDP-305 as a Monotherapy, Will Pursue Out-licensing Strategy Rather than Internal Development Benzinga

07:00AM EDT Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs Business Wire

Oct 1, 2021

07:00AM EDT Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting(r) 2021 Business Wire

Sep 16, 2021

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

Sep 9, 2021

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

06:28AM EDT SVB Leerink Initiates Coverage On Enanta Pharmaceuticals with Market Perform Rating, Announces Price Target of $55 Benzinga

Sep 7, 2021

07:00AM EDT Enanta Pharmaceuticals to Participate in Investor Conferences in September Business Wire

Sep 3, 2021

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 23, 2021

07:05AM EDT Enanta Pharma Elects Yujiro Hata To Board RTTNews

07:00AM EDT Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors Business Wire

Aug 16, 2021

07:07AM EDT Enanta Pharma Doses First Subject In Phase 1 Clinical Study Of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer RTTNews

07:03AM EDT Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer Benzinga

Aug 9, 2021

04:32PM EDT Enanta Pharmaceuticals Files For Potential Mixed Shelf Offering; Size Not Disclosed Benzinga

09:08AM EDT RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $50 Benzinga

Aug 6, 2021

09:33AM EDT JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Raises Price Target to $77 Benzinga

Aug 5, 2021

04:32PM EDT Enanta Pharmaceuticals: Q3 Earnings Insights Benzinga

04:32PM EDT Enanta Pharmaceuticals Q3 Adj. EPS $(1.19) Beats $(1.26) Estimate, Sales $21.62M Miss $22.14M Estimate Benzinga

04:31PM EDT Enanta Pharmaceuticals Q3 EPS $(1.19) Beats $(1.26) Estimate, Sales $21.62M Miss $22.14M Estimate Benzinga

04:01PM EDT Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

07:19AM EDT Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 Benzinga

07:19AM EDT Enanta Announces Nomination Of EDP-235, Lead Oral Protease Inhibitor Specifically Designed For Treatment Of COVID-19 RTTNews

07:00AM EDT Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 Business Wire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:00AM EDT Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021 Business Wire

Jul 14, 2021

05:30PM EDT Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D. Business Wire

Jun 24, 2021

10:03AM EDT UPDATE: Roth Capital On Enanta Pharmaceuticals: RNA Destabilizer EDP-721 Shows Preclinical Selectivity, Activity And Synergism With Nucleotide Analogue Therapy And Other Hepatitis B Core Inhibitors Benzinga

10:02AM EDT UPDATE: Roth Capital On Enanta Pharmaceuticals: Phase 1B Results For Core Inhibitor EDP-514 Highlight Added Benefits To All-Oral Combo In Viremic Hepatitis B Patients. Benzinga

09:52AM EDT Roth Capital Maintains Buy Rating On Enanta Pharmaceuticals, Price Target $107. Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

05:49AM EDT Enanta Pharmaceuticals Reported New Preclinical Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at EASL International Liver Congress; CEO Said Data Strongly Support the Continued Development of EDP-721 Benzinga

02:35AM EDT Enanta Pharma Presents New Data For EDP-721 At EASL International Liver Congress RTTNews

02:01AM EDT Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress(tm) Business Wire

Jun 22, 2021

04:18PM EDT Enanta Pharma Earlier Reported Data From Phase 1b Study Of Hep B Virus Core Inhibitor Candidate: 'was Safe and Well-Tolerated with Pharmacokinetics Supportive of Once-Daily, Oral Dosing' Benzinga

04:01PM EDT Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients Business Wire

Jun 10, 2021

07:00AM EDT Enanta Pharmaceuticals to Participate in Two Investor Conferences in June Business Wire

Jun 3, 2021

07:00AM EDT Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress(tm) 2021 Sponsored by the European Association for the Study of the Liver Business Wire

May 11, 2021

07:00AM EDT Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference Business Wire

May 7, 2021

09:58AM EDT Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA Benzinga

May 6, 2021

04:14PM EDT Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor Benzinga

04:01PM EDT Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire

04:01PM EDT Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor Business Wire

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 29, 2021

07:00AM EDT Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021 Business Wire

Mar 2, 2021

07:01AM EST Enanta Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire

Feb 18, 2021

04:02PM EST Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference Business Wire

Feb 8, 2021

05:06PM EST Recap: Enanta Pharmaceuticals Q1 Earnings Benzinga

04:13PM EST Enanta Pharmaceuticals Q1 EPS $(0.41) Beats $(0.74) Estimate, Sales $31.74M Beat $28.79M Estimate Benzinga

04:02PM EST Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire

04:04AM EST Earnings Scheduled For February 8, 2021 Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 5, 2021

10:09AM EST Earnings Preview: Enanta Pharmaceuticals Benzinga

Feb 1, 2021

04:02PM EST Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2020 Business Wire

Jan 29, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021 Benzinga

07:33AM EST JP Morgan Upgrades Enanta Pharmaceuticals to Neutral, Raises Price Target to $55 Benzinga

Jan 26, 2021

07:14AM EST Enanta Appoints Brendan Luu As SVP, Business Development RTTNews

07:00AM EST Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development Business Wire

Jan 8, 2021

07:11AM EST Enanta Pharma Says Looks Forward To Continuing Progress Throughout 2021 With Multiple Milestones RTTNews

07:01AM EST Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 5, 2021

07:04AM EST Enanta Pharmaceuticals Appoints John DeVincenzo As VP Of Translational Virology RTTNews

07:01AM EST Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology Business Wire

06:00AM EST Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 8, 2020

07:11AM EST Enanta Pharma Appoints Tara Kieffer As SVP, New Product Strategy And Development RTTNews

07:01AM EST Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development Business Wire

Nov 24, 2020

12:42PM EST Enanta Pharmaceuticals shares were trading lower after the company reported worse-than-expected Q4 EPS and sales results. Benzinga

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

05:52AM EST Evercore ISI Group Initiates Coverage On Enanta Pharmaceuticals with Underperform Rating, Announces Price Target of $30 Benzinga

Nov 23, 2020

04:20PM EST Enanta Pharmaceuticals: Q4 Earnings Insights Benzinga

04:14PM EST Enanta Pharmaceuticals Q4 Loss/share $1.46 Vs. Profit $0.44 Year Ago RTTNews

04:01PM EST Enanta Pharmaceuticals Q4 EPS $(1.46) Misses $(0.95) Estimate, Sales $23.63M Miss $25.74M Estimate Benzinga

04:01PM EST Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 Business Wire

04:05AM EST Earnings Scheduled For November 23, 2020 Benzinga

Nov 20, 2020

10:03AM EST Earnings Preview: Enanta Pharmaceuticals Benzinga

Nov 18, 2020

07:02AM EST Enanta Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire

Nov 16, 2020

07:02AM EST Enanta Pharmaceuticals to Host Conference Call on November 23 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 Business Wire

Sep 28, 2020

07:00AM EDT Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference Business Wire

Sep 14, 2020

07:06AM EDT Enanta Doses First Subjects In Its Phase 1 Clinical Trial Of EDP-297 RTTNews

07:04AM EDT Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-297 Targeted Follow-On Farnesoid X Receptor Agonist For Non-Alcoholic Steatohepatitis Benzinga

07:00AM EDT Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis Business Wire

Sep 3, 2020

07:01AM EDT Enanta Pharmaceuticals to Participate in Upcoming September Conferences Business Wire

Sep 1, 2020

03:18PM EDT Plasma Stocks Quiet; Reuters Reports NIH Advisors Say Data Fail To Back Trump-Backed Plasma Therapy Benzinga

Aug 28, 2020

07:15AM EDT Roth Capital Reinstates Buy on Enanta Pharmaceuticals, Announces $104 Price Target Benzinga

06:17AM EDT Enanta Pharmaceuticals To Present New Data From Its Hepatitis B And Non-Alcoholic Steatohepatitis Programs At The Digital International Liver Congress 2020 Benzinga

Aug 26, 2020

09:42AM EDT Benzinga's Top Upgrades, Downgrades For August 26, 2020 Benzinga

06:23AM EDT Piper Sandler Initiates Coverage On Enanta Pharmaceuticals with Overweight Rating, Announces Price Target of $87 Benzinga

Aug 20, 2020

07:04AM EDT Enanta Pharmaceuticals Announces Data Presentations At The European Association For The Study Of The Liver (EASL) Digital International Liver Congress 2020 Benzinga

Aug 4, 2020

04:21PM EDT Recap: Enanta Pharmaceuticals Q3 Earnings Benzinga

04:03PM EDT Enanta Pharmaceuticals Q3 EPS $(0.71) Beats $(0.77) Estimate, Sales $18.65M Miss $27.89M Estimate Benzinga

04:01PM EDT Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Aug 3, 2020

07:03AM EDT Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020 Business Wire

Jul 28, 2020

07:01AM EDT Enanta Pharmaceuticals to Host Conference Call on August 4 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2020 Business Wire

Jul 27, 2020

11:42AM EDT JMP Securities Upgrades Enanta Pharmaceuticals to Market Outperform, Announces $70 Price Target Benzinga